Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide.
Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro® is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 mg vial and Rs4,375 for a 5 mg vial, leading to a monthly cost of Rs14,000-Rs17,500, depending on dosage.